The Top 75: Williams-Labadie

Share this article:
When the recession visited 57 W. Grand St.—the Chicago home of Williams-Labadie—in late 2008, it didn't pack up and leave until the latter half of 2009. The mark left by this unwanted guest was indelible, but not an altogether bad one.

“It was a struggle,” acknowledges Peter Labadie, CEO, who was forced to lay off six. “I've been pleased to see…employee morale, which is key at agencies during tough times, has held together very well. We're stronger and tighter as a result.”

Business has started to turn around, too, and the agency has eight or nine months of “slow but steady growth from a lower baseline,” Labadie says. Revenue in 2009 was down only slightly from the year prior, and the agency has since hired back three of those let go. “This year's been way better than last year,” he reports. “Year to date, we're way ahead.”

That's due in part to five small wins; a diversified roster including professional, consumer and device work; and the firm's ability to hold onto most accounts. New arrivals include digital work for the American Medical Association and the US professional business for anesthetic Naropin from American Pharmaceutical Partners, plus two others Labadie declined to name. The firm also won back the Abbott Medical Optics Blink Tears Lubricating Eye Drops account, which involves both professional and consumer duties.

Departures in 2009 included SciClone Pharmaceuticals' immune system drug Zadaxin. Core client Smith & Nephew took away its wound-management product Allevyn. “I don't think people were shopping agencies,” Labadie comments. “I think it was more a question of cutting their spending.”

Another former client, deCode Genetics, went bankrupt before reemerging this year under private ownership. The losses followed the '08 patent expiry for blockbuster Prograf, a brand the agency had serviced for 15 years. The company behind Prograf, Astellas, is its longest-running account. Asked whether Astellas' $4-billion takeover of OSI in May could yield additional work, Labadie says it's too early to tell.

For the most part, the CEO says his agency has been able to keep existing business steady or from declining too much: “We managed to do good work and hold onto some budget while keeping declines minimal.” Activity from Astellas, Medicis Aesthetics and Abbott Medical Optics keeps the 49-person shop busy.

Its digital work, which now accounts for about half of business, is tracking upward. “The last year and first five months of this year have been an amplification of that [trend],” says Labadie, adding, “I could see a day down the road when every single thing we do is digital. It's heading in that direction, driven by clients.”

That trend is a double-edged sword, though. Labadie says clients increasingly expect that with digital marketing, they should be able to “do more with less and save money, but at the same time not reduce visibility in their target audience of HCPs or consumers, and possibly extend reach,” he observes. “That's a challenge all of us face.”

Being part of the Publicis Healthcare Communications Group makes it easier to execute targeted, analytics-based promotional campaigns. PHCG “has highly developed tools now in place across the network to bring the digital approach to life,” he says.

The goal for Williams-Labadie now is to recapture momentum. Says Labadie: “We can come back, and we think we're on our way to doing it.”
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Headliner: Proteus CEO takes an original path

Headliner: Proteus CEO takes an original path

Andrew Thompson, CEO, Proteus Digital Health

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...